respiratory

FOURIER shows new cholesterol drugs work, but are they worth it?

As it turns out the PCSK9 inhibitor saga ends not with a bang but a whimper. The results of the highly anticipated FOURIER trial show that the drugs work, though not as powerfully as many had hoped and expected. The question now will be whether the modest efficacy of the drugs is worth their immodest ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic